October 2nd, 2014   Today BioAxis Research and Okklo Life Sciences have entered into an exclusive collaboration for R&D projects. Their OCTOPlex technology contributes to the rapid development of specific sugar molecules, cyclodextrins, as potential treatment for various diseases. BioAxis Research BV and Okklo Life Sciences BV have unique expertise on the design and development …

Dr Martin Feiters and Prof Dr Floris Rutjes (Institute for Molecules and Materials, Radboud University Nijmegen, the Netherlands) and Okklo Life Sciences (Oss, The Netherlands) receive a KIEM-grant for their project  ‘Pervasive Cyclodextrins For Therapeutic Lipid Transfer’. In this project, a number of new cyclodextrins will be designed, synthesized and tested as potential medicines for …

Okklo Life Sciences partners with Dutch universities and SME Dr Jeroen Codee (Leiden Institute of Chemistry, Leiden), Prof Dr Hans Aerts (Medical Biochemistry, University of  Amsterdam) and  Dr  Daniel Zollinger (Okklo Life Sciences, Oss) receive a KIEM-grant for their project  ‘Designer cyclodextrins  & sphingolipids involved in lysosomal storage disease’. In this project, which also involves …

okklo life sciences As a biotech start-up company at the Pivot Park in Oss, The Netherlands, Okklo Life Sciences is building a project portfolio in orphan and neglected diseases. Our platform technology:  a targeted approach based on a chemical (cyclodextrin) platform. Apart from our on-going focus to expand our R&D collaboration network and expanding the number …

  On March 28th, okklo life sciences announces a new collaboration – the BiCycle platform ™. In partnership with two other biotech companies, BioConnection and ChemConnection (also located at the Pivot Park), this platform will deliver specialized services for the synthesis and manufacturing of GMP-quality drug products based on cyclodextrins. In addition, the platform will …